China Pharma (NYSE:CPHI) Trading Up 4% – Here’s What Happened

China Pharma Holdings, Inc. (NYSE:CPHI) was up 4% during trading on Wednesday . The stock traded as high as $0.6497 and last traded at $0.6420. Approximately 9,240 shares were traded during trading, a decline of 80% from the average daily volume of 46,505 shares. The stock had previously closed at $0.6175.

China Pharma Stock Up 4.0%

The stock has a market cap of $26.02 million, a PE ratio of -0.86 and a beta of 1.08. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.26 and a current ratio of 0.79. The company’s 50-day moving average price is $0.62 and its 200 day moving average price is $1.21.

Institutional Investors Weigh In On China Pharma

An institutional investor recently raised its position in China Pharma stock. Citadel Advisors LLC increased its position in China Pharma Holdings, Inc. (NYSE:CPHI) by 31.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,426 shares of the company’s stock after acquiring an additional 7,356 shares during the quarter. Citadel Advisors LLC owned about 0.93% of China Pharma worth $59,000 at the end of the most recent quarter.

China Pharma Company Profile

China Pharma Holdings, Inc develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People’s Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension.